Indaptus Therapeutics, Inc. Common Stock (INDP) Stock Price
INDPStock
$1.14−82.16%52W
Market Cap$151.90M
P/E—
PEG Ratio—
Div yield—
Beta1.10
INDP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-55.21%
Price vs S&P 500 (4W)-14.52%
VGM Score22.23
INDP Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q4 2025 | -$4.36 | -$9.19 | -110.78%(-$4.83) | |
| Q3 2025 | -$4.17 | -$2.98 | +28.54%(+$1.19) | |
| Q2 2025 | -$9.24 | -$9.09 | +1.62%(+$0.15) | |
| Q1 2025 | -$5.04 | -$8.96 | -77.78%(-$3.92) |
INDP Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INDPIndaptus Therapeutics, Inc. Common Stock | — | — | D | $1.14 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Indaptus Therapeutics, Inc. Common Stock
Indaptus Therapeutics is a pre-clinical biotechnology company developing a proprietary bacterial-based immunotherapy platform targeting cancer and viral infections. Its lead candidate, Decoy20, has demonstrated anti-tumor activity in preclinical models as both a single agent and in combination therapy across multiple cancer types, including colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.